Study Data from Mayo Clinic on Heart Failure Treatment Effectiveness Utilizing Daxor BVA-100 Presented at Key Scientific Meeting

Rhea-AI Summary

Daxor Corporation (Nasdaq: DXR) announced new findings from the Mayo Clinic at the Heart Failure Society of America meeting, revealing that over 50% of heart failure patients discharged from hospitals had suboptimal treatment based on BVA-100 blood tests. The study measured blood volume among 139 patients, showing persistent intravascular volume expansion post-discharge despite diuretic therapy. CEO Michael Feldschuh emphasized the urgency of blood volume analysis for improved patient outcomes, which could help reduce readmission rates penalized by the Centers for Medicare and Medicaid Services.

Positive

• New data reinforces BVA-100's effectiveness in identifying blood volume issues in heart failure patients.
• Study results highlight the importance of blood volume assessment for better patient outcomes and reduced readmission rates.

Negative

• Over 50% of patients were discharged with persistent intravascular volume expansion, indicating inadequacies in current treatment protocols.
• The study suggests a significant risk of readmission due to unresolved volume overload in heart failure patients.

Traditional Care: More than 50% Discharged From Hospital With Suboptimal Treatment

Oak Ridge, TN, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces new data from the Mayo Clinic in Rochester, NY validating the benefits of the Company’s BVA-100 blood test for patients with heart failure. Data were presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting – which brought together the world’s leading experts in heart failure on October 2nd, 2022, in Washington, DC.

The study titled “Impact of Right Ventricular Dysfunction of Blood Volume Expansion in Heart Failure” measured blood volume in 139 heart failure patients at the time of hospital discharge (post-diuretic therapy and considered to have a normal blood volume) utilizing the Daxor BVA-100 diagnostic blood test. Blood volume expansion was present in over 50% of the overall cohort with normal blood volume only present in 27% at the time of hospital discharge and a risk in particular for right ventricular dysfunction was highlighted as being particularly challenging. Despite treatment to resolve volume abnormalities, the study author noted “Persistent intravascular volume expansion is more common at the time of discharge despite diuretic intervention in heart failure,” said Wayne Miller, M.D., PhD, principal investigator.

Michael Feldschuh, CEO and President for Daxor said, “Heart failure management is centered around effective volume management. Many patients go home feeling better, but end up back in the hospital due to persistent volume overload. The Centers for Medicare and Medicaid Services (CMS) penalizes providers for patients who readmit within 30 days of discharge. This study adds to the considerable evidence that shows why blood volume analysis is urgently needed as it is the most sensitive and specific diagnostic tool for volume measurement in heart failure with significant outcome and cost improvements associated for patient care when used to guide treatment.”

About Daxor Corporation

Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100^® (Blood Volume Analyzer), the only diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 60,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing multicenter trials in the areas of COVID-19 and heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com.

Forward-Looking Statements

Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner, CORE IR
1-516-222-2560
brets@coreir.com

FAQ

What were the findings of Daxor's recent study presented at the Heart Failure Society of America meeting?

Daxor's study revealed that over 50% of discharged heart failure patients exhibited persistent blood volume expansion despite treatment, highlighting the need for better volume management.

How does the BVA-100 blood test benefit heart failure patients?

The BVA-100 blood test provides accurate blood volume measurements, helping healthcare providers manage heart failure more effectively and reduce hospital readmissions.

What is the implication of the new study findings for hospitals regarding patient discharge policies?

The findings suggest hospitals must reassess discharge practices to ensure effective volume management, potentially avoiding penalties from CMS for readmissions.

When and where was the study on heart failure patients presented?

The study was presented on October 2, 2022, at the Heart Failure Society of America Annual Scientific Meeting in Washington, DC.